{
    "clinical_study": {
        "@rank": "164706", 
        "arm_group": {
            "arm_group_label": "Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive CPI-613 IV over 2 hours on days 1-5, cytarabine IV over 3 hours every 12 hours for 5 doses beginning on day 3, and mitoxantrone hydrochloride IV over 15 minutes after the 1st, 3rd, and 5th doses of cytarabine. Treatment repeats every 14 days for up to 2 courses* in the absence of disease progression or unacceptable toxicity.\nNOTE: *Patients undergoing a second course of therapy receive CPI-613 IV over 2 hours on days 1-3, cytarabine IV over 3 hours every 12 hours for 5 doses beginning on day 2, and mitoxantrone hydrochloride IV over 15 minutes after the 1st and 3rd doses of cytarabine."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial studies the side effects and best dose of CPI-613 when given together\n      with cytarabine and mitoxantrone hydrochloride in treating patients with relapsed or\n      refractory acute myeloid leukemia. Drugs used in chemotherapy, such as CPI-613, cytarabine\n      and mitoxantrone hydrochloride, work in different ways to stop the growth of cancer cells,\n      either by killing the cells or by stopping them from dividing. CPI-613 may help cytarabine\n      and mitoxantrone hydrochloride work better by making cancer cells more sensitive to the\n      drugs"
        }, 
        "brief_title": "CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", 
        "condition": [
            "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", 
            "Adult Acute Myeloid Leukemia With Del(5q)", 
            "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", 
            "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", 
            "Recurrent Adult Acute Myeloid Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the safety and maximum tolerated dose (MTD) of CPI-613 when administered\n      with high dose cytarabine, and mitoxantrone (mitoxantrone hydrochloride).\n\n      SECONDARY OBJECTIVES:\n\n      I. To determine the pharmacokinetics (PKs) of CPI-613 following intravenous (IV)\n      administration in combination with high dose cytarabine and mitoxantrone.\n\n      II. To observe the response rate (complete response [CR], complete response with incomplete\n      platelet recovery [CRi] and partial response [PR]) of CPI-613 in combination with high dose\n      cytarabine and mitoxantrone.\n\n      III. To observe the overall survival of patients treated with CPI-613 in combination with\n      high dose cytarabine and mitoxantrone.\n\n      OUTLINE: This is a dose-escalation study of CPI-613.\n\n      Patients receive CPI-613 intravenously (IV) over 2 hours on days 1-5, cytarabine IV over 3\n      hours every 12 hours for 5 doses beginning on day 3, and mitoxantrone hydrochloride IV over\n      15 minutes after the 1st, 3rd, and 5th doses of cytarabine. . Treatment repeats every 14\n      days for up to 2 courses* in the absence of disease progression or unacceptable toxicity.\n\n      NOTE: *Patients undergoing a second course of therapy receive CPI-613 IV over 2 hours on\n      days 1-3, cytarabine IV over 3 hours every 12 hours for 5 doses beginning on day 2, and\n      mitoxantrone hydrochloride IV over 15 minutes after the 1st and 3rd doses of cytarabine.\n\n      After completion of study treatment, patients are followed up for 6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologically or cytologically documented relapsed and/or\n             refractory acute myeloid leukemia\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of \u2264 3\n\n          -  Expected survival > 3 months\n\n          -  Women of child-bearing potential (i.e., women who are pre-menopausal or not\n             surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine\n             device [IUD], oral contraceptive or double barrier device), and must have a negative\n             serum or urine pregnancy test within 1 week prior to treatment initiation; (Note:\n             Pregnant patients are excluded because the effects of CPI-613 on a fetus are unknown)\n\n          -  Fertile men must practice effective contraceptive methods during the study period,\n             unless documentation of infertility exists\n\n          -  Mentally competent, ability to understand and willingness to sign the informed\n             consent form\n\n          -  No radiotherapy, treatment with cytotoxic agents (except CPI-613), treatment with\n             biologic agents or any anti-cancer therapy within the 2 weeks prior to treatment with\n             CPI-613; patients must have fully recovered from the acute, non-hematological,\n             non-infectious toxicities of any prior treatment with cytotoxic drugs, radiotherapy\n             or other anti-cancer modalities (returned to baseline status as noted before most\n             recent treatment); patients with persisting, non-hematologic, non-infectious\n             toxicities from prior treatment \u2264 grade 2 are eligible, but must be documented as\n             such\n\n          -  Aspartate aminotransferase ([AST]/serum glutamic oxaloacetic transaminase [SGOT]) =<\n             3 x upper normal limit (UNL), alanine aminotransferase ([ALT]/serum glutamate\n             pyruvate transaminase [SGPT]) =< 3 x UNL (=< 5 x upper limit of normal [ULN] if liver\n             metastases present)\n\n          -  Bilirubin =< 1.5 x UNL\n\n          -  Serum creatinine =< 1.5 mg/dL or 133 \u03bcmol/L\n\n          -  International Normalized Ratio or INR must be < 1.5\n\n        Exclusion Criteria:\n\n          -  Serious medical illness, such as significant cardiac disease (e.g. symptomatic\n             congestive heart failure, unstable angina pectoris, myocardial infarction within the\n             past 6 months, uncontrolled cardiac arrhythmia, pericardial disease or New York Heart\n             Association class III or IV), or severe debilitating pulmonary disease, that would\n             potentially increase patients' risk for toxicity\n\n          -  Patients with active central nervous system (CNS) or epidural tumor\n\n          -  Any active uncontrolled bleeding, and any patients with a bleeding diathesis (e.g.,\n             active peptic ulcer disease)\n\n          -  Pregnant women, or women of child-bearing potential not using reliable means of\n             contraception (because the teratogenic potential of CPI-613 is unknown)\n\n          -  Lactating females because the potential of excretion of CPI-613 into breast milk\n             (Note: Lactating females are excluded because the effects of CPI-613 on a nursing\n             child are unknown)\n\n          -  Fertile men unwilling to practice contraceptive methods during the study period\n\n          -  Life expectancy less than 3 months\n\n          -  Any condition or abnormality which may, in the opinion of the investigator,\n             compromise the safety of patients\n\n          -  Unwilling or unable to follow protocol requirements\n\n          -  Patients with large and recurrent pleural or peritoneal effusions requiring frequent\n             drainage (e.g. weekly); patients with any amount of clinically significant\n             pericardial effusion\n\n          -  Active heart disease including myocardial infarction within previous 6 months,\n             symptomatic coronary artery disease, uncontrolled arrhythmias, or symptomatic\n             congestive heart failure\n\n          -  Albumin < 2.0 g/dL or < 20 g/L\n\n          -  Evidence of ongoing, uncontrolled infection\n\n          -  Patients with known human immunodeficiency virus (HIV) infection; (Note: Patients\n             with known HIV infection are excluded because patients with an immune deficiency are\n             at increased risk of lethal infections when treated with marrow-suppressive therapy,\n             and because there may be unknown or dangerous drug interactions between CPI-613 and\n             anti-retroviral agents used to treat HIV infections)\n\n          -  Patients receiving any other standard or investigational treatment for their cancer,\n             or any other investigational agent for any indication within the past 2 weeks prior\n             to initiation of CPI-613 treatment (the use of Hydrea is allowed)\n\n          -  Patients who have received immunotherapy of any type within the past 4 weeks prior to\n             initiation of CPI-613 treatment\n\n          -  Requirement for immediate palliative treatment of any kind including surgery\n\n          -  Patients that have received a chemotherapy regimen with stem cell support in the\n             previous 6 months\n\n          -  A history of additional risk factors for torsade de pointes (e.g., clinically\n             significant heart failure, hypokalemia, family history of long QT syndrome)\n\n          -  Troponin I above institutional limit of normal"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768897", 
            "org_study_id": "CCCWFU 22112", 
            "secondary_id": [
                "NCI-2012-02768", 
                "P30CA012197"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)", 
                "description": "Given IV", 
                "intervention_name": "CPI-613", 
                "intervention_type": "Drug", 
                "other_name": [
                    "alpha-lipoic acid analogue CPI-613", 
                    "CPI-613"
                ]
            }, 
            {
                "arm_group_label": "Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)", 
                "description": "Given IV", 
                "intervention_name": "cytarabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ARA-C", 
                    "arabinofuranosylcytosine", 
                    "arabinosylcytosine", 
                    "Cytosar-U", 
                    "cytosine arabinoside"
                ]
            }, 
            {
                "arm_group_label": "Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)", 
                "description": "Given IV", 
                "intervention_name": "mitoxantrone hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CL 232315", 
                    "DHAD", 
                    "DHAQ", 
                    "Novantrone"
                ]
            }, 
            {
                "arm_group_label": "Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)", 
                "description": "Optional correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Mitoxantrone", 
                "Thioctic Acid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 28, 2014", 
        "location": {
            "contact": {
                "email": "tspardee@wfubmc.edu", 
                "last_name": "Timothy S. Pardee", 
                "phone": "336-713-6771"
            }, 
            "facility": {
                "address": {
                    "city": "Winston-Salem", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27157"
                }, 
                "name": "Comprehensive Cancer Center of Wake Forest University"
            }, 
            "investigator": {
                "last_name": "Timothy S. Pardee", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)", 
        "overall_official": {
            "affiliation": "Comprehensive Cancer Center of Wake Forest University", 
            "last_name": "Timothy Pardee", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "MTD of CPI-613 based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE 3.0)", 
            "safety_issue": "Yes", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768897"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Confidence intervals will be calculated.", 
                "measure": "Response rate (CR, CRi, and PR)", 
                "safety_issue": "No", 
                "time_frame": "Day 14 of course 1"
            }, 
            {
                "description": "We will use Kaplan-Meier estimation.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }
        ], 
        "source": "Comprehensive Cancer Center of Wake Forest University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Comprehensive Cancer Center of Wake Forest University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}